Eris Lifesciences to Review Preferential Issue Plan for Swiss Parenterals Acquisition on November 24

Eris Lifesciences has announced that its Board will meet on November 24, 2025, to consider issuing equity shares through a preferential issue as part of its plan to acquire the remaining 30% stake in Swiss Parenterals. 

Eris Lifesciences Board to Assess Preferential Issue for 30% Stake Buyout 

The company has notified the exchanges that it will review a proposal to issue equity shares for consideration other than cash to complete the acquisition of the remaining 30% equity stake in Swiss Parenterals. This move aligns with regulatory provisions under the Companies Act, SEBI Listing Regulations, and SEBI ICDR norms. If approved, the transaction would allow the company to consolidate full ownership without direct cash expenditure. 

Board to Consider Shareholder Approval Route 

The Board will also evaluate the process of seeking shareholder consent through an Extraordinary General Meeting or postal ballot. This approval is essential before moving ahead with the preferential issue structure. 

Read More: Shilpa Medicare Q2 FY26 Earnings Results Out: PAT Surges 146% YoY! 

Regulatory and Procedural Compliance 

Eris Lifesciences has indicated that the preferential issue will be carried out in adherence with statutory and regulatory requirements. The potential acquisition would offer the company complete control over Swiss Parenterals’ operations, strengthening its manufacturing and pharma capabilities. 

Eris Lifesciences Share Price Performance 

As of November 19, 2025, at 2:54 PM, Eris Lifesciences share price was trading at ₹1,610.10 up by 2.18% from the previous closing price. 

Conclusion 

The upcoming Board meeting marks an important milestone for Eris Lifesciences as it considers a preferential issue to acquire the remaining 30% stake in Swiss Parenterals. The proposal is subject to regulatory compliance and shareholder approval, with the final decision expected after the Board’s review on November 24, 2025. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.